Viridian Therapeutics Inc (VRDN NASDAQ) stock market data APIs
$17.2264
-0.28(-1.6%)
as of July 10, 2025
Try our APIs with
free plan!
Viridian Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. The company's product pipeline includes veligrotug, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R monoclonal antibodies targeting IGF-1R and engineered of half-life extension technology, which is in Phase 3 clinical trial for the treatment of TED. It also develops portfolio of engineered anti-neonatal Fc receptor inhibitors, such as VRDN-006 and VRDN-008 for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.
Prev. Close
17.2264
Open
16.9428
High
17.2228
Low
16.696
52 wk Range
9.9-27.2
Market Cap
1 390 M
Shares Outstanding
81 592 K
Revenue
302 K
EPS
-0.869
Beta
0.461
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Viridian Therapeutics Inc data using free add-ons & libraries
Get Viridian Therapeutics Inc Fundamental Data
Viridian Therapeutics Inc Fundamental data includes:
- Net Revenue: 302 K
- EBITDA: -336 492 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-06
- EPS/Forecast: -1.1
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Viridian Therapeutics Inc News
New
Viridian Therapeutics' SWOT analysis: promising TED treatment stock faces pivotal year
Viridian Therapeutics, Inc. (NASDAQ:VRDN), a $1.29 billion market cap biopharmaceutical company focused on developing treatments for thyroid eye disease (TED), stands at a critical juncture in its jou...
Viridian Issues Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(RTTNews) - Viridian Therapeutics, Inc. (VRDN) has granted non-qualified stock options to purchase 23,400 shares of its common stock to a new employee as part of an inducement grant, effective June 2,...
State Street Corp's Strategic Reduction in Viridian Therapeutics Inc
Overview of the Recent Trade On September 30, 2024, State Street Corp executed a significant transaction involving Viridian Therapeutics Inc (NASDAQ:VRDN), a key player in the biopharmaceutical indus...
12 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds
In this article we present the list of 12 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds. Click to skip past our discussion of the biotech space and straight to the 5 B...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
